Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine
- PMID: 15708844
- PMCID: PMC552808
- DOI: 10.1136/bmj.38356.655266.82
Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine
Erratum in
- BMJ. 2005 Apr 2;330(7494):759. Dosage error in article text
Abstract
Objective: To investigate the efficacy of hypericum extract WS 5570 (St John's wort) compared with paroxetine in patients with moderate to severe major depression.
Design: Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial.
Setting: 21 psychiatric primary care practices in Germany.
Participants: 251 adult outpatients with acute major depression with total score > or = 22 on the 17 item Hamilton depression scale.
Interventions: 900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders doses were increased to 1800 mg/day hypericum or 40 mg/day paroxetine after two weeks.
Main outcome measures: Change in score on Hamilton depression scale from baseline to day 42 (primary outcome). Secondary measures were change in scores on Montgomery-Asberg depression rating scale, clinical global impressions, and Beck depression inventory.
Results: The Hamilton depression total score decreased by mean 14.4 (SD 8.8) points, corresponding to 56.6% (SD 34.3%) of the baseline value, in the hypericum group and by 11.4 (SD 8.6) points (44.8% (SD 33.5%) of baseline value) in the paroxetine group (intention to treat analysis; similar results were observed in the per protocol analysis). The intention to treat analysis (lower one sided 97.5% confidence limit 1.5 points for the difference hypericum minus paroxetine) and the per protocol analysis (lower confidence limit 0.7 points) showed non-inferiority of hypericum and statistical superiority over paroxetine. The lower limits in both cases exceeded the pre-specified non-inferiority margin of -2.5 points and the superiority margin of 0. The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine, respectively.
Conclusions: In the treatment of moderate to severe major depression, hypericum extract WS 5570 is at least as effective as paroxetine and is better tolerated.
Figures
Comment in
-
St John's wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated.Evid Based Ment Health. 2005 Nov;8(4):107. doi: 10.1136/ebmh.8.4.107. Evid Based Ment Health. 2005. PMID: 16246883 No abstract available.
-
St John's wort versus paroxetine for depression.Can Fam Physician. 2007 Sep;53(9):1511-3. Can Fam Physician. 2007. PMID: 17872882 Free PMC article. No abstract available.
Similar articles
-
Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.Pharmacopsychiatry. 2006 Nov;39(6):213-9. doi: 10.1055/s-2006-951388. Pharmacopsychiatry. 2006. PMID: 17124643 Clinical Trial.
-
Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].BMC Med. 2006 Jun 23;4:14. doi: 10.1186/1741-7015-4-14. BMC Med. 2006. PMID: 16796730 Free PMC article. Clinical Trial.
-
Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.Am J Psychiatry. 2002 Aug;159(8):1361-6. doi: 10.1176/appi.ajp.159.8.1361. Am J Psychiatry. 2002. PMID: 12153829 Clinical Trial.
-
Hypericum extract WS ® 5570 for depression--an overview.Int J Psychiatry Clin Pract. 2013 Nov;17 Suppl 1:1-7. doi: 10.3109/13651501.2013.813554. Int J Psychiatry Clin Pract. 2013. PMID: 23808616 Review.
-
Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials.Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):59-63. doi: 10.1007/s00406-007-0779-2. Epub 2007 Dec 14. Eur Arch Psychiatry Clin Neurosci. 2008. PMID: 18084790 Review.
Cited by
-
Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments.Front Pharmacol. 2023 Sep 28;14:1234701. doi: 10.3389/fphar.2023.1234701. eCollection 2023. Front Pharmacol. 2023. PMID: 37841934 Free PMC article.
-
The antidepressant effect of combined extracts of Hypericum perforatum and Echium amoenum supplementation in patients with depression symptoms: A randomized clinical trial.Avicenna J Phytomed. 2023 Jul-Aug;13(4):328-337. doi: 10.22038/AJP.2023.21707. Avicenna J Phytomed. 2023. PMID: 37663381 Free PMC article.
-
A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.Psychedelic Med (New Rochelle). 2023 Mar;1(1):18-26. doi: 10.1089/psymed.2022.0002. Epub 2022 Oct 28. Psychedelic Med (New Rochelle). 2023. PMID: 37337526 Free PMC article.
-
Hypericum perforatum: Traditional uses, clinical trials, and drug interactions.Iran J Basic Med Sci. 2022 Sep;25(9):1045-1058. doi: 10.22038/IJBMS.2022.65112.14338. Iran J Basic Med Sci. 2022. PMID: 36246064 Free PMC article. Review.
-
Antidepressant Effects of a Persian Medicine Remedy on Multiple Sclerosis Patients: A Double-Blinded Randomized Clinical Trial.Galen Med J. 2019 Jan 1;8:e1212. doi: 10.31661/gmj.v8i0.1212. eCollection 2019. Galen Med J. 2019. PMID: 34466472 Free PMC article.
References
-
- Linde K, Mulrow CD. St John's wort for depression. Cochrane Database Syst Rev 2004;(4): CD000448. - PubMed
-
- Harrer G, Hübner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatric Psychiatry Neurol 1994;7(suppl 1): S24-8. - PubMed
-
- Vorbach EU, Hübner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatric Psychiatry Neurol 1994;7(suppl 1): S19-23. - PubMed
-
- Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients—a controlled 6-week clinical trial. Pharmacopsychiatry 1997;30(suppl 2): 77-80. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical